The deal size was increased to $401M from $300M and priced below last closing price of $39.96. TD Cowen, Leerink, Cantor Fitzgerald, Barclays and Wells Fargo are acting as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences files to sell $300M in common stock
- Avidity Biosciences price target raised to $56 from $38 at Leerink
- Avidity Biosciences price target raised to $45 from $40 at Evercore ISI
- Avidity Biosciences price target raised to $45 from $33 at Chardan
- Avidity Biosciences: Promising Trials and Strategic Growth Initiatives